Human immunodeficiency virus type 1 (HIV-1) viral protein R (Vpr) interacts with Lys-tRNA synthetase: Implications for priming of HIV-1 reverse transcription

Journal of Virology

Volumn 72, Issue 4, 1998, Pages 3037-3044

  Stark, Lesley A ^a,b   Hay, Ronald T ^a  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RIBONUCLEIC ACID SYNTHETASE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; ENZYME BINDING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; LIFE CYCLE; PRIORITY JOURNAL; PROTEIN INTERACTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; VIRUS PATHOGENESIS;

EID: 0031901250     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.4.3037-3044.1998     Document Type: Article

References (73)

1. Agostini, I., J. M. Navarro, F. Rey, M. Bouhamdan, B. Spire, R. Vigne, and J. Sire. 1996. The human immunodeficiency virus type 1 Vpr transactivator - cooperation with promoter bound activator domains and binding to TFIIB. J. Mol. Biol. 261:599-606.
2. Bachelerie, F., J. Alcami, F. Arenzana-Seisdedos, and J.-L. Virelizier. 1991. HIV enhancer activity perpetuated by NF-κB induction on infection of monocytes. Nature 350:709-712.
3. Balotta, C., P. Lusso, R. Crowley, R. C. Gallo, and G. Franchini. 1993. Antisense phosphorothioate oligonucleotides targeted to the vpr gene inhibit human immunodefeciency virus type 1 replication in primary human macrophages. J Virol. 67:4409-1414.
4. 2 accumulation by a mechanism which differs from DNA damage checkpoint control. J. Virol. 70:2324-2331.
5. Beiser, C. 1997. Recent advances - HIV infection. 2. Br. Med. J. 314:379-583.
6. Bouhamdan, M., S. Benichou, F. Rey, J.-M. Navarro, I. Agostini, B. Spire, J. Camonis, G. Slupphaug, R. Vigne, R. Benarous, and J. Sire. 1996. Human immunodefeciency virus type 1 Vpr protein binds to the uracil DNA glycosylase DNA repair enzyme. J. Virol. 70:697-704.
7. Breeden, L., and K. Nasmyth. 1985. Regulation of the yeast HO gene. Cold Spring Harbor Symp. Quant. Biol. 50:643-650.
8. Cohn, J. A. 1997. Recent advances - HIV infection. 1. Br. Med. J. 314: 487-491.
9. lys. J. Mol. Biol. 253:100-113.
10. Conner I. B., B. K. Chen, S. Choe, and N. R. Landau. 1995. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mono-nuclear phagocytes. Virology 206:936-944.
11. Cullen, B. R., and W. C. Green. 1990. Functions of the auxilary gene products of the human immunodeficiency virus type 1. Virology 178:1-5.
12. Cusack, S., M. Hartlein, and R. Leberman. 1991. Sequence structural and evolutionary relationships between class II aminoacyl-tRNA synthetases. Nucleic Acids Res. 19:3489-3498.
13. Dang, C. V., R. L. Glinski, P. C. Gainey, and R. H. Hilderman. 1982. Physical and biochemical characterisation of a purified arginyl-tRNA synthetase-lysyl-tRNA synthetase complex from rat liver. Biochemistry 21:1959-1966.
14. Delarue, M. 1995. Aminoacyl-tRNA synthetases. Curr. Opin. Struct. Biol. 5: 48-55.
15. DeNoronha, C. M. C., A. Takaorikondo, M. McEntree, and W. C. Greene. 1996. The HIV vpr protein causes G2 cell cycle arrest by interacting with and enhancing protein phosphatase 2A function. Mol. Biol. Cell 7:2064.
16. Durfee, T., K. Becherer, P.-L. Chen, S. H. Yeh, Y. Yang, A. E. Kilburn, W-H. Lee, and S. J. Elledge. 1993. The retinoblastoma protein associates with the protein phosphatase type 1 catalytic subunit. Genes Dev. 7:555-569.
17. Emerman, M. 1996. HIV-1, Vpr and the cell cycle. Curr. Biol. 6:1096-1103.
18. Gelpi, C., E. Kanterewicz, J. Gratacos, I. N. Targoff, and J. L. Rodriguez-Sanchez. 1996. Coexistence of two antisynthetases in a patient with the antisynthetase syndrome. Arthritis Rheum. 39:692-697.
19. Gietz, D., A. St Jean, R. A. Woods, and R. H. Schiestl. 1992. Improved method for high efficiency transformation of intact yeast cells. Nucleic Acids Res. 20:1425.
20. Grigoreva, A. Y. 1994. Structure of aminoacyl transfer RNA synthetases in higher eukaryotes based on molecular cloning data. Mol. Biol. 28:630-638.
21. Guthrie, C., and G. R. Fink. 1991. Guide to yeast genetics and molecular biology. Methods Enzymol. 194:3-21.
22. Hattori, N., F. Michaels, K. Fargnoli, L. Marcon, R. C. Gallo, and G. Franchini. 1990. The human immunodeficiency type 2 gene is essential for productive infection of human macrophages. Proc. Natl. Acad. Sci. USA 87: 8080-8084.
23. cdc2 activity. J. Virol. 69:6705-6711.
24. Heinzinger, N. K., M. I. Bukrinsky, S. A. Haggerty, A. M. Ragland, V. Kewalramani, M.-A. Lee, H. E. Gendelman, L. Ratner, M. Stevenson, and M. Emerman. 1994. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in non dividing host cells. Proc. Natl. Acad. Sci. USA 91:7311-7315.
25. Hoch, J., S. M. Lang, M. Weeger, C. Stahlhennig, C. Coulibaly, U. Dittmer, G. Hunsmann, D. Fuchs, J. Muller, S. Sopper, B. Fleckenstein, and K. T. Uberla. 1995. Vpr deletion mutant of simian immunodefeciency virus induces AIDS in rhesus monkeys. J. Virol. 69:4807-4813.
26. Hoffman, C. S., and F. Winston. 1985. A ten-minute DNA preparation from yeast effeciently releases autonomous plasmids for transformation of Escherichia coli. Gene 57:267-272.
27. Lys into human immunodeficiency virus type 1. J. Virol. 68:7676-7683.
28. Lys anticodon on the initiation of human immunodeficiency virus type 1 reverse transcription. J. Virol. 70:4700-4706.
29. Igarashi, T., Y. Ami, H. Yamamoto, R. Shibata, T. Kuwata, R. Mukai, K. Shinohara, T. Komatsu, A. Adachi, and M. Hayami. 1997. Protection of monkeys vaccinated with vpr- and/or nef-defective simian immunodeficiency virus strain mac human immunodefeciency virus type 1 chimeric viruses: a potential candidate live-attenuated human AIDS vaccine. J. Gen. Virol. 78: 985-989.
30. lys (template/primer) complex. J. Mol. Biol. 247: 236-250.
31. lys. EMBO J. 15:917-924.
32. Jayaraman, P.-S., K. Hirst, and C. R. Goding. 1994. The activation domain of a basic-helix-loop-helix protein is masked by repressor interaction with domains distinct from that required for transcription regulation. EMBO J. 13:2192-2199.
33. Jiang, M., J. Mak, A. Ladha, E. Cohn, M. Klein, B. Rovinski, and L. Kleiman. 1993. Identification of tRNAs incorporated into the wild-type and mutant human immunodeficiency virus type 1. J. Virol. 67:3246-3253.
34. 2 + M phase of the cell cycle. J. Virol. 69:6304-6313.
35. Kishore, G. M., and D. M. Sha. 1988. Amino acid biosynthesis inhibitors and herbicides. Annu. Rev. Biochem. 57:627-663.
36. gag required for the incorporation of human immunodeficiency virus type 1 Vpr. J. Virol. 70:159-164.
37. Lang, S. M., M. Weeger, C. Stahl-Hennig, C. Coulibaly, G. Hunsmann, J. Muller, H. Muller-Hermelink, D. Fuchs, H. Wachter, M. M. Daniel, R. C. Desrosiers, and B. Fleckenstein. 1993. Importance of Vpr for infection of rhesus monkeys with simian immunodeficiency virus. J. Virol. 67:902-912.
38. gag precursor for incorporation of the vpr product into human immunodefiency virus type 1 viral particles. J. Virol. 68:1926-1934.
39. Levy, D. N., L. S. Fernandes, W. V. Williams, and D. B. Weiner. 1993. Induction of cell differentiation by human immunodeficiency virus 1 vpr. Cell 72:541-550.
40. Levy, D. N., Y. Refaeli, R. R. MacGregor, and D. B. Weiner. 1994. Serum vpr regulates productive infection and latency of human immunodefeciency type 1. Proc. Natl. Acad. Sci. USA 91:10873-10877.
41. Levy, D. N., Y. Refaeli, and D. B. Weiner. 1995. Extracellular Vpr protein increases cellular permissiveness to human immunodeficiency virus replication and reactivates virus from latency. J. Virol. 69:1243-1252.
42. Li, M.-S., G. Garcia-Asua, U. Bhattacharyya, P. Mascagni, B. M. Austen, and M. M. Roberts. 1996. The Vpr protein of human immunodefeciency virus type 1 binds to nucleocapsid protein p7 in vitro. Biochem. Biophys. Res. Commun. 218:352-355.
43. Lin, L., S. P. Hale, and P. Schimmel. 1996. Aminoacylation error correction. Nature 384:33-34.
44. Lys3. Role of reverse transcriptase. Trends Biochem. Sci. 3:114-118.
45. Lu, Y.-L., P. Spearman, and L. Ratner. 1993. Human immunodefeciency virus type 1 viral protein R localisation in infected cells and virions. J. Virol. 67:6542-6550.
46. gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles. J. Virol. 69: 6873-6879.
47. Macreadie, I. G., L. A. Castelli, D. R. Hewish, A. Kirkpatrick, A. C. Ward, and A. A. Azad. 1995. A domain of human immunodeficiency virus type 1 Vpr containing repeated H(S/F)RIG amino acid motifs causes cell growth arrest and structural defects. Proc. Natl. Acad. Sci. USA 92:2770-2774.
48. gag-pol in mediating the selective incorporation of tRNA-Lys into human immunodeficiency virus type 1 particles. J. Virol. 68:2065-2072.
49. Martinez, R., and M. Mirande. 1992. The polyanion binding domain of cytoplasmic lys-transfer RNA synthetase from Saccharomyces cerevisiae is not essential for cell viability. Eur. J. Biochem. 207:1-11.
50. Marzio, P. D., S. Choe, M. Ebright, R. Knoblauch, and N. R. Landau. 1995. Mutational analysis of cell cycle arrest, nuclear localization, and virion packaging of human immunodeficiency virus type 1 Vpr. J. Virol. 69:7909-7916.
51. Miller, R. H., and N. Sarver. 1997. HIV accessory proteins as therapeutic targets. Nat. Med. 3:389-394.
52. Nomura, N., N. Miyajima, T. Sazuka, A. Tanaka, Y. Kawarabayashi, T. Nagase, K. Ishikawa, T. Seki, and S. Tabata. Unpublished data.
53. Paxton, W., R. I. Connor, and N. R. Landau. 1993. Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis. J. Virol. 67:7229-7237.
54. Planelles, V., F. Bachelerie, J. B. M. Jowett, A. Haislip, Y. Xie, P. Banooni, T. Masuda, and I. S. Y. Chen. 1995. Fate of human immunodeficiency virus type 1 provirus in infected cells - a role for Vpr. J. Virol. 69:5883-5889.
55. Planelles, V., J. B. M. Jowett, Q.-X. Li, Y. Xie, B. Hahn, and I. S. Y. Chen. 1996. Vpr-induced cell cycle arrest is conserved among primate lentiviruses. J. Virol. 70:2516-2524.
56. Refaeli Y., D. N. Levy, and D. B. Weiner. 1995. The glucocorticoid receptor type II complex is a target of the HIV-1 vpr gene product. Proc. Natl. Acad. Sci. USA 92:3621-3625.
57. Rogel, M. E., L. I. Wu, and M. Emerman. 1995. The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection. J. Virol. 69:882-888.
58. Saluta, M. V., and I. N. Hirshfield. 1995. The occurrence of duplicate lysyl-tRNA synthetase gene homologs in Escherichia coli and other procaryotes. J. Bacteriol. 177:1872-1878.
59. Schmidt, E., and P. Schimmel. 1995. Mutational isolation of a sieve for editing in a transfer RNA synthetase. Science 264:265-267.
60. Senger, B., L. Despons, P. Walter, and F. Fasiolo. 1992. The anticodon triplet is not sufficient to confer methionine acceptance to a transfer RNA. Proc. Natl. Acad. Sci. USA 89:10768-10771.
61. Smith, D. B., and K. S. Johnson. 1988. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene 67:31-40.
62. Subbramanian, R. A., and E. A. Cohen. 1994. Molecular biology of the human immunodeficiency virus accessory proteins. J. Virol. 68:6831-6835.
63. Tristem, M., C. Marshall, A. Karpas, and F. Hill. 1992. Evolution of the primate lentiviruses: evidence from vpx and vpr. EMBO J. 11:3405-3412.
64. Trono, D. 1995. HIV accessory proteins - leading roles for the supporting cast. Cell 82:189-192.
65. 0 by HIV-1 encoded complex NCp7:Vpr. FEBS Lett. 401:197-201.
66. Votjek, A. B., S. M. Hollenberg, and J. A. Cooper. 1993. Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell 74:205-214.
67. Wang, L., S. Mukherjee, F. Jia, O. Narayan, and L-J. Zhao. 1995. Interaction of virion protein Vpr of human immunodeficiency virus type 1 with cellular transcription factor Sp1 and trans-activation of viral long terminal repeat. J. Biol. Chem. 270:25564-25569.
68. Wang, L. L., S. Mukherjee, O. Narayan, and L. J. Zhao. 1996. Characterization of a leucine zipper like domain in vpr protein of human immunodeficiency virus tvpe 1. Gene 178:7-13.
69. Webster, A., I. R. Leith, and R. T. Hay. 1994. Activation of adenovirus-coded protease and processing of the preterminal protein. J. Virol. 68:7292-7300.
70. Westervelt, P., T. Henkel, D. B. Trowbridge, J. Orenstein, J. Heuser, H. E. Gendelman, and L. Ratner. 1992. Dual regulation of silent and productive infection in monocytes by distinct human immunodeficiency virus type 1 determinants. J. Virol. 66:3925-3931.
71. Yao, X-J., R. A. Subbramanian, N. Rougeau, F. Boisvert, D. Bergeron, and E. A. Cohen. 1995. Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation. J. Virol. 69:7032-7044.
72. Zhao, L.-J., S. Mukherjee, and O. Narayan. 1994. Biochemical mechanisms of HIV-1 vpr function. J. Biol. Chem. 269:15577-15582.
73. Zhao, Y. Q., J. A. Cao, M. R. G. Ogorman, M. Yu, and R. Yogev. 1996. Effect of human immunodeficiency virus type 1 protein R (Vpr) gene expression on basic cellular function of fission yeast Schizosaccharomyces pombe. J. Virol. 70:5821-5826.